Orchestra BioMed (NASDAQ:OBIO) Posts Earnings Results, Beats Expectations By $0.07 EPS

Orchestra BioMed (NASDAQ:OBIO) announced its quarterly earnings data on Tuesday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07, FiscalAI reports. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million.

Orchestra BioMed Stock Performance

Shares of OBIO traded up $0.15 on Tuesday, reaching $4.06. The company’s stock had a trading volume of 137,644 shares, compared to its average volume of 203,480. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.45 and a quick ratio of 6.43. The stock has a market capitalization of $243.12 million, a P/E ratio of -3.59 and a beta of 0.52. The stock’s 50 day simple moving average is $4.33 and its two-hundred day simple moving average is $4.26. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42.

Insider Buying and Selling

In other news, insider David P. Hochman bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the insider owned 1,086,467 shares of the company’s stock, valued at approximately $4,660,943.43. This represents a 0.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC bought a new stake in Orchestra BioMed in the 2nd quarter valued at $118,000. Bank of America Corp DE increased its holdings in Orchestra BioMed by 42.0% in the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock valued at $95,000 after acquiring an additional 7,036 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Orchestra BioMed in the 4th quarter valued at $76,000. Tower Research Capital LLC TRC increased its holdings in Orchestra BioMed by 1,137.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 27,922 shares of the company’s stock valued at $75,000 after acquiring an additional 25,666 shares during the last quarter. Finally, Cresset Asset Management LLC bought a new stake in Orchestra BioMed in the 3rd quarter valued at $74,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on OBIO. Wall Street Zen raised Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings cut Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.